
|Videos|February 16, 2023
Case 3: Faricimab in a neovascular nAMD patient with persistent fluid
Advertisement
Dr. Khanani discusses how switching to faricimab helped resolve persistent intraretinal and subretinal fluid in a patient and extended treatment intervals leading to decreased patient burden.
Sponsored by Roche
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
Eyes on June 2026: Approvals, pipeline momentum, and AI under the microscope
4
Understanding meibomian gland dysfunction, neuropathic pain, and the evolving dry eye patient
5





















